Michelino De Laurentiis, Chair of Department of Breast and Thoracic Oncology at National Cancer Institute ‘Fondazione Pascale’, shared a post on LinkedIn about a recent article he and her colleagues co-authored, adding:
“We are pleased to share our article, ‘In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast Cancer,’ just published in JCO as a response to the commentary by Ian F. Tannock and colleagues, ‘Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.’
In our reply, we critically address key issues raised by Tannock et al.—including treatment duration, toxicity, cost-effectiveness, and methodological aspects of the monarchE and NATALEE trials—providing an evidence-based and biologically grounded perspective.
This exchange exemplifies constructive scientific dialogue on a pivotal question for clinical oncology and the future of adjuvant therapy in HR+/HER2– breast cancer.”
Title: In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast Cancer
Authors: Michelino De Laurentiis, Roberto Buonaiuto, Giuseppe Buono, Roberta Caputo, Carmine De Angelis
Read the Full Article on JCO
More posts featuring Michelino De Laurentiis.